Immunic (IMUX) News Today → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Free IMUX Stock Alerts $1.23 -0.01 (-0.81%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28, 2024 | prnewswire.comImmunic to Participate in Industry and Scientific Conferences in JuneMay 23, 2024 | marketbeat.comQ2 2024 Earnings Estimate for Immunic, Inc. Issued By Brookline Capital Management (NASDAQ:IMUX)Immunic, Inc. (NASDAQ:IMUX - Free Report) - Analysts at Brookline Capital Management decreased their Q2 2024 earnings per share (EPS) estimates for Immunic in a research report issued on Monday, May 20th. Brookline Capital Management analyst T. Bussian now anticipates that the company will post eMay 23, 2024 | investorplace.comPeek Behind the Curtain: 7 Penny Stocks With Heavy Insider BuyingMay 21, 2024 | theglobeandmail.comImmunic CMO discusses role of clinical trials in biotech development for Clinical Trials DayMay 10, 2024 | markets.businessinsider.comHold Rating on Immunic Amidst Ongoing Vido Clinical Trials and Financial OutlookMay 9, 2024 | finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comWe Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth CarefullyMay 8, 2024 | msn.comIMUX Stock Earnings: Immunic Misses EPS for Q1 2024May 8, 2024 | proactiveinvestors.comImmunic advances ‘potentially groundbreaking' MS therapy vidofludimus calcium during Q1May 8, 2024 | prnewswire.comImmunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 7, 2024 | msn.comImmunic Q1 2024 Earnings PreviewMay 6, 2024 | prnewswire.comImmunic to Participate in Investor and Scientific Conferences in MayMay 3, 2024 | benzinga.comImmunic Stock (NASDAQ:IMUX), Quotes and News SummaryMay 2, 2024 | marketbeat.comImmunic (IMUX) to Release Earnings on WednesdayImmunic (NASDAQ:IMUX) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.May 1, 2024 | prnewswire.comImmunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate UpdateApril 30, 2024 | proactiveinvestors.comImmunic publishes extended data from Phase 2 MS trial in peer-reviewed journalApril 30, 2024 | prnewswire.comImmunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & NeuroinflammationApril 29, 2024 | finance.yahoo.comImmunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial roleApril 19, 2024 | marketbeat.comImmunic (NASDAQ:IMUX) Upgraded by StockNews.com to "Hold"StockNews.com upgraded Immunic from a "sell" rating to a "hold" rating in a report on Friday.April 19, 2024 | finance.yahoo.comImmunic, Inc. (IMUX)April 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)April 15, 2024 | marketbeat.comShort Interest in Immunic, Inc. (NASDAQ:IMUX) Rises By 22.7%Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 3,030,000 shares, an increase of 22.7% from the March 15th total of 2,470,000 shares. Based on an average daily volume of 976,400 shares, the days-to-cover ratio is presently 3.1 days.April 12, 2024 | morningstar.comImmunic Inc IMUXApril 5, 2024 | msn.comBrookline Capital starts Immunic at buy, cites MS drug candidateApril 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Shockwave Medical (SWAV)April 5, 2024 | marketbeat.comImmunic (NASDAQ:IMUX) Research Coverage Started at Brookline Capital ManagementBrookline Capital Management started coverage on Immunic in a research note on Friday. They issued a "buy" rating and a $10.00 target price for the company.April 4, 2024 | finance.yahoo.comWith 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investorsApril 4, 2024 | finance.yahoo.comImmunic to Host MS R&D Day and Participate in Investor Conferences in AprilApril 1, 2024 | marketbeat.comShort Interest in Immunic, Inc. (NASDAQ:IMUX) Expands By 11.3%Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 2,470,000 shares, an increase of 11.3% from the February 29th total of 2,220,000 shares. Based on an average daily trading volume, of 977,100 shares, the short-interest ratio is currently 2.5 days.March 29, 2024 | marketbeat.comImmunic (NASDAQ:IMUX) Downgraded to "Sell" at StockNews.comStockNews.com lowered shares of Immunic from a "hold" rating to a "sell" rating in a report on Friday.March 20, 2024 | marketwatch.comImmunic Gets Allowance for Vidofludimus Calcium Patent ApplicationMarch 20, 2024 | proactiveinvestors.comImmunic granted patent for specific polymorph of vidofludimus calcium in USMarch 20, 2024 | prnewswire.comImmunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United StatesMarch 18, 2024 | marketbeat.comShort Interest in Immunic, Inc. (NASDAQ:IMUX) Declines By 11.9%Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the recipient of a significant drop in short interest in the month of February. As of February 29th, there was short interest totalling 2,220,000 shares, a drop of 11.9% from the February 14th total of 2,520,000 shares. Based on an average daily volume of 943,800 shares, the short-interest ratio is presently 2.4 days.March 18, 2024 | proactiveinvestors.comImmunic CMO discusses complexities of multiple sclerosis to mark MS Awareness MonthMarch 11, 2024 | marketbeat.comImmunic (NASDAQ:IMUX) Upgraded to Hold at StockNews.comStockNews.com raised Immunic from a "sell" rating to a "hold" rating in a research note on Monday.March 7, 2024 | prnewswire.comImmunic to Participate in Investor and Scientific Conferences in MarchFebruary 29, 2024 | proactiveinvestors.comImmunic to present data for lead asset vidofludimus calcium from Phase 2 MS and COVID-19 trialsFebruary 29, 2024 | prnewswire.comImmunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024February 26, 2024 | markets.businessinsider.comHold Rating on Immunic: Balancing Long-Term Potential Against Short-Term UncertaintiesFebruary 23, 2024 | finance.yahoo.comImmunic Inc (IMUX) Reports Year-End 2023 Financial ResultsFebruary 23, 2024 | finance.yahoo.comImmunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immunic Amid Progress in IMU-838 Trials and Extended Financial RunwayFebruary 22, 2024 | proactiveinvestors.comImmunic expects financial stability through 2025 as MS clinical programs advanceFebruary 22, 2024 | proactiveinvestors.comImmunic reports successful 2023 and prepares for key 2025 milestonesFebruary 22, 2024 | finance.yahoo.comImmunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate UpdateFebruary 22, 2024 | prnewswire.comImmunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate UpdateFebruary 21, 2024 | benzinga.comImmunic Stock (NASDAQ:IMUX) Dividends: History, Yield and DatesFebruary 21, 2024 | benzinga.comImmunic's Earnings OutlookFebruary 16, 2024 | marketbeat.comImmunic (IMUX) to Release Earnings on ThursdayImmunic (NASDAQ:IMUX) will be releasing earnings before the market opens on Thursday, February 22, Zacks reports. Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address Hurry! Buy this stock before the Robinhood traders do! (Ad)Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942%, and 12,592% in 2020. Now their next one could be here. Click here to pay just $5 for a full year of Stealth Trades IMUX Media Mentions By Week IMUX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMUX News Sentiment▼0.000.76▲Average Medical News Sentiment IMUX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMUX Articles This Week▼02▲IMUX Articles Average Week Get Immunic News Delivered to You Automatically Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Verve Therapeutics News Erasca News Biomea Fusion News Lexicon Pharmaceuticals News Neurogene News Theravance Biopharma News Terns Pharmaceuticals News Acelyrin News Esperion Therapeutics News FibroBiologics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMUX) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored